Inhibikase Therapeutics Stock (NASDAQ:IKT)

Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This candidate aims to address not only Parkinson's disease itself but also early-stage gastrointestinal complications often experienced by PD patients, such as swallowing difficulties (dysphagia), neurologically-induced constipation, and multiple system atrophy. Additionally, Inhibikase is advancing IkT-001Pro through preclinical development. This prodrug, derived from the anti-cancer agent Imatinib, is intended to lessen typical gastrointestinal side effects while providing treatment for blood and stomach cancers. Beyond these primary compounds, the company is also pursuing various research programs focused on other neurological disorders. Inhibikase actively collaborates on research and development initiatives with several prominent academic institutions, including The Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Established in 2008, Inhibikase Therapeutics, Inc. maintains its corporate headquarters in Atlanta, Georgia.